Phase 1/2 study of alectinib in RET-rearranged previously-treated non-small cell lung cancer (ALL-RET)

BACKGROUND: Rearranged during transfection (RET) rearrangements occur in 1–2% of non-small cell lung cancers (NSCLCs). Alectinib administered at doses of 300 mg and 600 mg twice daily (BID) is approved for ALK: rearranged NSCLC in Japan and other countries, respectively. Since alectinib has activity...

Descripción completa

Detalles Bibliográficos
Autores principales: Takeuchi, Shinji, Yanagitani, Noriko, Seto, Takashi, Hattori, Yoshihiro, Ohashi, Kadoaki, Morise, Masahiro, Matsumoto, Shingo, Yoh, Kiyotaka, Goto, Koichi, Nishio, Makoto, Takahara, Shizuko, Kawakami, Takahiro, Imai, Yasuhito, Yoshimura, Kenichi, Tanimoto, Azusa, Nishiyama, Akihiro, Murayama, Toshinori, Yano, Seiji
Formato: Online Artículo Texto
Lenguaje:English
Publicado: AME Publishing Company 2021
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7867784/
https://www.ncbi.nlm.nih.gov/pubmed/33569315
http://dx.doi.org/10.21037/tlcr-20-549

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7867784/
https://www.ncbi.nlm.nih.gov/pubmed/33569315
http://dx.doi.org/10.21037/tlcr-20-549

Ejemplares similares